Skip to main content

Table 2 Comparative susceptibility to cefiderocol versus ceftazidime–avibactam, ceftolozane–tazobactam, imipenem–relebactam, meropenem–vaborbactam, colistin of Gram-negative bacterial species

From: Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence

 

Cefiderocol

Ceftazidime–avibactam

Ceftolozane–tazobactam

Imipenem–relebactam

Meropenem–vaborbactam

Colistina

Refs

 

MIC90

(µg/mL)

Susceptibility

rate (%)

MIC90

(µg/mL)

Susceptibility

rate (%)

MIC90

(µg/mL)

Susceptibility

rate (%)

MIC90

(µg/mL)

Susceptibility

rate (%)

MIC90

(µg/mL)

Susceptibility

rate (%)

MIC90

(µg/mL)

Susceptibility

rate (%)

 

CLSI

EUCAST

CLSI

EUCAST

 

CLSI

EUCAST

 

CLSI

EUCAST

 

CLSI

EUCAST

 

CLSI

EUCAST

 

Enterobacterales

1

99.8

98.3

0.5

99.2

NR

2

91.7

NR

NT

NT

NT

NT

NT

NT

1

96.8

NR

[28]

0.5

99.8

99.1

0.25

99.5

99.5

NT

NT

NT

0.5

94.8

98.9b

0.06

99.4

99.5

 > 8

83.6

83.6

[30]

CRE

4

96.7

79.9

 > 64

77.0

NR

 > 64

7.8

NR

NT

NT

NT

NT

NT

NT

 > 8

80.5

NR

[28]

4

98.2

87.6

 > 32

81.7

81.7

NT

NT

NT

 > 8

63.9

71.0b

 > 8

71.0

75.7

 > 8

78.7

78.7

[30]

M/V-R Enterobacterales

4

95.1

70.7

 > 32

43.9

43.9

NT

NT

NT

 > 8

2.4

7.3b

 > 8

0

0

 > 8

48.8

48.8

[30]

I/R-R Enterobacterales

4

95.9

69.4

 > 32

40.8

40.8

NT

NT

NT

 > 8

0

0b

 > 8

16.3

24.5

 > 8

55.1

55.1

[30]

CZA-R Enterobacterales

8

89.2

54.1

 > 32

0

0

NT

NT

NT

 > 8

5.4

8.1b

 > 8

29.7

37.8

 > 8

56.8

56.8

[30]

P. aeruginosa

0.5

99.9

99.4

8

93.8

NR

2

94.0

NR

NT

NT

NT

NT

NT

NT

2

99.3

NR

[28]

0.5

99.6

99.4

4

96.4

96.4

2

96.1

96.1

1

96.4

96.4

NT

NT

NT

1

99.6

99.6

[30]

CR P. aeruginosa

1

99.8

98.5

32

75.0

NR

 > 64

76.1

NR

NT

NT

NT

NT

NT

NT

1

98.5

NR

[28]

XDR P. aeruginosa

1

97.3

96.9

32

73.4

73.4

 > 16

72.3

72.3

 > 8

73.0

73.0

NT

NT

NT

1

99.2

99.2

[30]

XDR P. aeruginosa

4

97.4

NA

 > 16

57.0

NA

32

66.8

NA

16

49.8

NA

NT

NT

NT

NT

NT

NT

[128]

C/T-R P. aeruginosa

8

88.3

85.0

 > 32

25.0

25.0

 > 16

0

0

 > 8

43.3

43.3

NT

NT

NT

1

100

100

[30]

I/R-R P. aeruginosa

1

100

100

 > 32

35.4

35.4

 > 16

20.8

20.8

 > 8

0

0

NT

NT

NT

1

100

100

[30]

CZA-R P. aeruginosa

4

91.6

89.2

 > 32

0

0

 > 16

37.3

37.3

 > 8

47.0

47.0

NT

NT

NT

1

100

100

[30]

A. baumannii

1

96.0

94.1

 > 64

NA

NA

 > 64

NA

NA

NT

NT

NT

NT

NT

NT

2

92.7

NR

[28]

1

97.7

95.7c

NT

NT

NT

NT

NT

NT

 > 8

53.1

53.1

NT

NT

NT

8

86.3

86.3

[30]

CR A. baumannii

2

94.2

91.1

 > 64

NA

NA

 > 64

NA

NA

NT

NT

NT

NT

NT

NT

 > 8

87.2

NR

[28]

2

95.8

91.5c

NT

NT

NT

NT

NT

NT

 > 8

0.3

0.3

NT

NT

NT

 > 8

76.4

76.4

[30]

S. maltophilia

0.25

98.6

99.6

64

NA

NA

 > 64

NA

NA

NT

NT

NT

NT

NT

NT

 > 8

NA

NA

[28]

0.5

97.9

99.7c

NT

NT

NT

NT

NT

NT

NT

NT

NT

NT

NT

NT

 > 8

NA

NA

[30]

Achromobacter spp.

0.5

NA

NA

16

NA

NA

NT

NT

NT

2

NA

NA

4

NA

NA

4

NA

NA

[29]

CR Achromobacter spp.

4

NA

NA

 > 16

NA

NA

NT

NT

NT

 > 16

NA

NA

 > 16

NA

NA

8

NA

NA

[29]

Burkholderia spp.

0.5

NA

NA

8

NA

NA

32

NA

NA

NT

NT

NT

NT

NT

NT

 > 8

NA

NA

[28]

0.5

NA

NA

8

NA

NA

32

NA

NA

4

NA

NA

4

NA

NA

 > 8

NA

NA

[147]

CR Burkholderia spp.

1

NA

NA

16

NA

NA

 > 64

NA

NA

4

NA

NA

4

NA

NA

 > 8

NA

NA

[147]

  1. Adapted from [28,29,30, 128, 147]
  2. CFDC cefiderocol, CLSI Clinical and Laboratory Standards Institute, COL colistin, CR carbapenem resistant, CRE carbapenem-resistant Enterobacterales, CZA ceftazidime–avibactam, C/T ceftolozane–tazobactam, I/R imipenem–relebactam, MIC minimum inhibitory concentration, M/V meropenem–vaborbactam, NA susceptibility breakpoint not available, NR not reported, NT not tested, R resistant, XDR extensively drug resistant
  3. aOnly intermediate category is applicable by CLSI
  4. bCLSI/FDA breakpoints were applied to all species but were approved for Enterobacterales except Morganella, Proteus, and Providencia and EUCAST excludes Morganellaceae
  5. cEUCAST non-species-specific PK/PD breakpoint used